biologic

PENBRAYA

Meningococcal Groups A, B, C, W, and Y Vaccine

Loss of exclusivityOctober 2035projected — 12-year biologic exclusivity estimate
CompanyPfizer Ireland Pharmaceuticals Unlimited Company

Drug detail

Brand namePENBRAYA
Active ingredientMeningococcal Groups A, B, C, W, and Y Vaccine
Strength5UG
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalOctober 2023
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

PENBRAYA patent cliff — loss of exclusivity October 2035 | CliffBio